Anti-GDF15 Antibody Neoadjuvant Therapy for Bladder Cancer Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neoadjuvant therapies for muscle-invasive bladder cancer (MIBC) provide only a small survival benefit and are associated with high recurrence rates, necessitating the development of more effective treatment strategies that can downstage tumors and improve immune responses before surgery.
Innovation Solution
The use of an anti-GDF-15 antibody, such as visugromab, in combination with checkpoint inhibitors like anti-PD-1 antibodies, to enhance tumor-selective immune influx and potentially achieve pathologic complete response (pCR) in primary tumors, allowing for efficient immune cell delivery before surgery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neoadjuvant chemotherapy is administered for muscle-invasive bladder cancer, then tumor size reduction is achieved, but survival improvement is limited (only approx. 6% at 5 years)
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy to immunotherapy targeting GDF-15. The anti-GDF-15 antibody (visugromab) blocks the growth differentiation factor 15 pathway, fundamentally altering the mechanism of action to achieve superior survival benefits while maintaining tumor response rates.
Solution Approach 2:
The patent introduces an intermediary substance - the anti-GDF-15 antibody - that mediates the immune system's response against cancer cells. This antibody acts as a bridge between the patient's immune system and the tumor, enhancing immune-mediated tumor killing without direct cytotoxicity like chemotherapy.
2Reliability
If radical cystectomy is performed for muscle-invasive bladder cancer, then complete tumor removal is achieved, but high recurrence rate (up to 50% within 12 months) occurs
Solution Approach 1:
The patent applies preliminary action by administering anti-GDF-15 therapy before surgery to downstage the tumor and eliminate micrometastases. This pre-treatment prepares the patient by reducing tumor burden and addressing circulating cancer cells before the radical cystectomy, thereby lowering recurrence risk after complete surgical removal.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining immune activation against GDF-15 targets both before and after surgery. The therapy continues to exert antitumoral effects post-operatively, providing ongoing protection against recurrence rather than allowing immune activity to cease after the surgical intervention.
3Reliability
If conventional neoadjuvant therapy is used, then treatment is administered, but high death rate (50%-70% at 5 years) remains despite aggressive treatment
Solution Approach 1:
The patent substitutes the mechanical/cytotoxic mechanism of chemotherapy with an immunological mechanism. Instead of directly killing cells through chemical agents, the anti-GDF-15 antibody activates the immune system to recognize and destroy cancer cells, resulting in more durable and effective survival outcomes.
Data Source
AI summary
The present invention relates to an anti-GDF15 antibody for use in a neoadjuvant therapy of cancer.